The systemic administration of the anti-HMGB1 monoclonal antibody (mAb) in animal models of stroke, brain trauma, and epilepsy significantly inhibited the translocation and release of HMGB1 from neurons, thus protecting the BBB from disruption [4,9,10,11,12]. This evidence concerns the gene HMGB1 and stroke disorder.